Filgotinib

The long-term management of autoimmune diseases has long been confronted with the clinical challenge of balancing efficacy and safety. The advent of JAK inhibitors has opened up a new path for the treatment of such diseases. As a representative variety of JAK1 selective inhibitors, filgotinib can precisely block the signal transduction of pro-inflammatory cytokines such as IL-6 and IFN-γ mediated by JAK1, so as to reduce inflammatory responses and excessive activation of immune cells. At present, it has been approved for the treatment of adult patients with rheumatoid arthritis who have inadequate response to conventional therapy or biological agents. Meanwhile, it has also shown significant efficacy in clinical studies for indications such as ulcerative colitis and Crohn's disease, providing a safer medication option for patients intolerant to other JAK inhibitors.

The global market size of filgotinib had exceeded 970 million US dollars in 2023, with a compound annual growth rate of over 32% in the past three years. The growth momentum mainly comes from the rising prevalence of autoimmune diseases and the increasing recognition of highly selective JAK inhibitors among clinicians. At present, the global market is dominated by the original research product, with Europe and North America as the core consumption regions, accounting for 78% of the total global sales. The domestic market is still in the introduction period: only the original research preparation has been approved for marketing, and no generic drug has been approved, so the potential clinical demand has not been fully released.

The original research enterprise of filgotinib is Gilead Sciences, and the original research trade name is Jyseleca. Its European compound patent will expire in 2032, and the core patent in the United States will expire in 2033. The dosage form approved for the original research product is tablet, with two specifications of 100mg and 200mg, which has been included in the reference preparation catalogs of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Up to now, no filgotinib active pharmaceutical ingredient (API) has been registered through the Center for Drug Evaluation (CDE) in China, and only the original research 200mg tablet was approved for marketing by the National Medical Products Administration (NMPA) in 2023. Domestic preparation imitation and API research and development are still in the early stage. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of filgotinib impurity reference standards. Most products are in regular stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All products meet the requirements of multiple national regulations including the Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for API research and development, quality research and generic drug consistency evaluation.